Bicycle Therapeutics (BCYC) Debt to Equity: 2020-2024
Historic Debt to Equity for Bicycle Therapeutics (BCYC) over the last 3 years, with Jun 2024 value amounting to $0.04.
- Bicycle Therapeutics' Debt to Equity fell 74.48% to $0.04 in Q2 2024 from the same period last year, while for Jun 2024 it was $0.04, marking a year-over-year decrease of 74.48%. This contributed to the annual value of $0.08 for FY2023, which is 26.08% down from last year.
- Latest data reveals that Bicycle Therapeutics reported Debt to Equity of $0.04 as of Q2 2024, which was down 59.11% from $0.09 recorded in Q1 2024.
- Over the past 5 years, Bicycle Therapeutics' Debt to Equity peaked at $0.21 during Q2 2021, and registered a low of $0.04 during Q2 2024.
- Moreover, its 3-year median value for Debt to Equity was $0.09 (2022), whereas its average is $0.09.
- As far as peak fluctuations go, Bicycle Therapeutics' Debt to Equity soared by 43.21% in 2023, and later plummeted by 74.48% in 2024.
- Over the past 5 years, Bicycle Therapeutics' Debt to Equity (Quarterly) stood at $0.15 in 2020, then slumped by 43.22% to $0.09 in 2021, then increased by 29.76% to $0.11 in 2022, then dropped by 26.08% to $0.08 in 2023, then plummeted by 74.48% to $0.04 in 2024.
- Its Debt to Equity stands at $0.04 for Q2 2024, versus $0.09 for Q1 2024 and $0.08 for Q4 2023.